Avian Influenza Clinical Trial
Official title:
A Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of One Single Intravenous Dose and 5-day Repeated Intravenous Doses of FBF001 in Healthy Male Subjects
The purpose of this study is to assess the clinical and laboratory safety and to determine the pharmacokinetic profile of FBF001.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01698060 -
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
|
Phase 1 | |
| Completed |
NCT02213354 -
H7N9 Mix and Match With MF59 in Healthy Elderly Persons
|
Phase 2 | |
| Completed |
NCT00561184 -
Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine
|
Phase 2 | |
| Completed |
NCT02921997 -
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
|
Phase 2 | |
| Completed |
NCT03682120 -
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
|
Phase 2 | |
| Completed |
NCT00895544 -
Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT02251288 -
A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
|
Phase 1 | |
| Completed |
NCT02612909 -
A Safety and Immunogenicity Study of IVACFLU-A/H5N1
|
Phase 2/Phase 3 | |
| Completed |
NCT02229357 -
Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine
|
Phase 2 | |
| Completed |
NCT01150552 -
Studies of Avian Influenza Transmission to Humans in Egypt
|
N/A | |
| Completed |
NCT03472976 -
H5N1 With or Without Topical Aldara in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01897701 -
A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1
|
Phase 1 | |
| Completed |
NCT01107262 -
Avian Influenza Studies In Lebanon
|
N/A | |
| Completed |
NCT02839330 -
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
|
Phase 3 | |
| Completed |
NCT03014310 -
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology
|
Phase 1 | |
| Completed |
NCT00298233 -
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
|
Phase 2 | |
| Completed |
NCT03318315 -
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
|
Phase 2 | |
| Completed |
NCT03312231 -
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
|
Phase 2 | |
| Completed |
NCT03738241 -
2017 A/H7N9 IIV Revaccination
|
Phase 2 | |
| Completed |
NCT03589807 -
2013/2017 H7N9 Prime-Boost Interval
|
Phase 2 |